Understanding how the immune environment affects chemotherapy resistance in colorectal cancer
Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms: a Patient-derived Tumoroids Prospective Collection From Systemic Treatment Naive Tumors
This study is trying to understand how the immune system around colorectal cancer affects how well chemotherapy works, aiming to help patients who are about to have surgery and haven't started treatment yet.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Grenoble) |
| Trial ID | NCT05038358 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the mechanisms of chemoresistance in colorectal cancer by developing tumoroids from fresh human primary colonic tumor tissue. It focuses on the role of the immune microenvironment in influencing tumor response to chemotherapy. By analyzing these tumoroids, researchers hope to identify new predictive markers for treatment response and develop personalized medicine strategies. The study targets patients with colorectal adenocarcinoma who are scheduled for surgical resection and have not yet received chemotherapy.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with colorectal adenocarcinoma who are scheduled for immediate surgical resection and have not received prior chemotherapy.
Not a fit: Patients who are pregnant, breastfeeding, minors, or have certain viral infections (HIV, HBV, HCV) may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for colorectal cancer patients, enhancing their response to chemotherapy.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in understanding tumor microenvironments and their impact on treatment responses.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female over 18 years old. * Managed at the CHUGA for a colorectal adenocarcinoma * With an indication for immediate surgical resection as part of the care. * Patient naive from neo-adjuvant chemotherapy * Patient did not object to the CRC-ORGA-2 study Exclusion Criteria: * Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress). * Patients with positive HIV, HBV, HCV serology.
Where this trial is running
Grenoble
- University Hospital of Grenoble Alpes — Grenoble, France (Recruiting)
Study contacts
- Principal investigator: Gael Roth, Md, Phd — university hospital of Grenoble alpes
- Study coordinator: Gael Roth, Md, Phd
- Email: GRoth@chu-grenoble.fr
- Phone: 04 76 76 51 68
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.